Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Exelixis, Inc. (NASDAQ:EXEL) have been assigned a consensus recommendation of “Moderate Buy” from the twenty analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $37.59.

Several brokerages recently issued reports on EXEL. Truist Financial increased their price objective on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. BMO Capital Markets downgraded Exelixis from an “outperform” rating to a “market perform” rating and increased their price target for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. Guggenheim restated a “buy” rating and issued a $42.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $41.00 price objective on shares of Exelixis in a research note on Thursday, January 23rd. Finally, Brookline Capital Management started coverage on shares of Exelixis in a report on Monday, December 23rd. They issued a “buy” rating for the company.

Exelixis Stock Down 0.0 %

Shares of Exelixis stock opened at $37.71 on Friday. The stock’s fifty day moving average is $35.70 and its two-hundred day moving average is $33.09. Exelixis has a 52 week low of $20.14 and a 52 week high of $40.02. The company has a market capitalization of $10.55 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, research analysts anticipate that Exelixis will post 2.04 earnings per share for the current year.

Insider Buying and Selling

In other Exelixis news, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total transaction of $388,000.00. Following the completion of the sale, the executive vice president now owns 341,028 shares in the company, valued at $13,231,886.40. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock worth $5,177,234 in the last 90 days. Insiders own 2.85% of the company’s stock.

Hedge Funds Weigh In On Exelixis

Several institutional investors and hedge funds have recently modified their holdings of EXEL. Victory Capital Management Inc. lifted its stake in shares of Exelixis by 16.6% in the 3rd quarter. Victory Capital Management Inc. now owns 136,178 shares of the biotechnology company’s stock valued at $3,534,000 after purchasing an additional 19,372 shares during the period. CIBC Asset Management Inc purchased a new position in shares of Exelixis in the 3rd quarter valued at about $227,000. Natixis Advisors LLC increased its stake in shares of Exelixis by 26.2% in the 3rd quarter. Natixis Advisors LLC now owns 29,113 shares of the biotechnology company’s stock valued at $755,000 after purchasing an additional 6,051 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Exelixis during the third quarter worth approximately $1,972,000. Finally, Advisors Asset Management Inc. grew its holdings in Exelixis by 3.2% in the third quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock valued at $515,000 after purchasing an additional 609 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.